Psoriatic arthritis, a chronic autoimmune condition, links psoriasis with joint inflammation, affecting skin, nails, eyes, ...

Some people with psoriatic arthritis (PsA) may have a disease that is difficult to manage (D2M) or does not respond to ...

Every year on 29 October, World Psoriasis Day raises awareness of the 125 million people worldwide living with PsA ...

Defining difficult-to-manage and treatment-refractory disease — Some people with psoriatic arthritis (PsA) may have disease that is difficult to ...

UCB, a global biopharmaceutical company, today announced new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX (R) (bimekizumab-bkzx) in adults with active ...

Some people with psoriatic arthritis (PsA) may have disease that is difficult to manage (D2M) or does not respond to ...

NAILS: The inflammation throughout the body from PsA and PsO can affect the nail beds as well. The symptoms can range from minor nail weakening and swelling of the nail bed to pitting (dents on the ...

Autoimmune diseases can affect just about every part of the body – and tens of millions of people. While most common in women ...

Disease activity and multimorbidity among patients in the US with PsA varied based on geographic region, socioeconomic deprivation, race, and gender.

The global psoriasis treatment market is projected to expand at a compound annual growth rate (CAGR) of 8.5% by 2026. Key factors fueling this growth include the rising prevalence of psoriasis, ...

In two replicate Phase 3 studies, upadacitinib (RINVOQ ® ) achieved the co-primary endpoints of 50% reduction in Total Vitiligo Area Scoring Index (T-VASI 50) from baseline and 75% reduction in Facial ...

Samsung Bioepis has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of ...